{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:39:20Z","timestamp":1788925160682,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtct.2022.11.004","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T03:13:03Z","timestamp":1667963583000},"page":"108.e1-108.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients"],"prefix":"10.1016","volume":"29","author":[{"given":"Aditi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-5705","authenticated-orcid":false,"given":"Vijendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8871","authenticated-orcid":false,"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.11.004_bib0001","unstructured":"US Food and Drug Administration (FDA): 2017 Biological license application approvals. April 3, 2018. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/2017-biological-license-application-approvals. Accessed XXX."},{"key":"10.1016\/j.jtct.2022.11.004_bib0002","unstructured":"US Food and Drug Administration (FDA): 2018 Biological license application supplement noteworthy approvals. January 31, 2019. Available at: www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/2018-biological-license-application-supplement-noteworthy-approvals. Accessed January 3, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0003","unstructured":"US Food and Drug Administration (FDA): 2021 Biological license application supplement noteworthy approvals. December 20, 2021. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/2021-biological-license-application-supplement-noteworthy-approvals. Accessed January 3, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0004","unstructured":"US Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. March 7, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed March 26, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.11.004_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2022.11.004_bib0007","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.11.004_bib0008","doi-asserted-by":"crossref","first-page":"928","DOI":"10.6004\/jnccn.2020.7678","article-title":"Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy","volume":"19","author":"Johnson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2022.11.004_bib0009","unstructured":"BMT Infonet. Medical centers offering CAR T-cell therapy. January 3, 2022. Available at: https:\/\/www.bmtinfonet.org\/medical-centers-offering-car-t-cell-therapy. Accessed XXX."},{"key":"10.1016\/j.jtct.2022.11.004_bib0010","unstructured":"Healthcare Cost and Utilization Project (HCUP). Partner organizations providing data to HCUP. Available at: https:\/\/www.hcup-us.ahrq.gov\/db\/hcupdatapartners.jsp. Accessed XXX."},{"key":"10.1016\/j.jtct.2022.11.004_bib0011","unstructured":"Healthcare Cost and Utilization Project. HCUP Data use agreement training. Available at: https:\/\/www.hcup-us.ahrq.gov\/tech_assist\/dua.jsp. Accessed January 3, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0012","unstructured":"Healthcare Cost and Utilization Project. Introduction to the HCUP Nationwide Readmissions Database (NRD), 2010-2018. December 2020. Available at: https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nrd\/Introduction_NRD_2010-2018.jsp. Accessed February 22, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0013","unstructured":"Kolenikov S. Epctile-estimation and inference for percentiles. Available at: http:\/\/staskolenikov.net\/stata. Accessed August 4, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0014","unstructured":"Russo A, Wier LM, Elixhauser A, Healthcare Cost and Utilization Project. Hospital utilization among near-elderly adults, ages 55 to 64 years, 2007. Statistical brief #79. September 2009. Available at: https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb79.pdf. Accessed Feburary 22, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0015","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2022.11.004_bib0016","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Cancer stat facts: non-Hodgkin lymphoma. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed February 22, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0017","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Cancer stat facts: myeloma. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed February 22, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0018","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Cancer stat facts: leukemia. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html. Accessed February 22, 2022."},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.11.004_bib0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood-2018-99-112254","article-title":"Analysis of hospitalization and readmissions after CAR T cell therapy","volume":"132","author":"O'Donnell","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.11.004_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtct.2022.11.004_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.11.004_bib0022","unstructured":"Centers for Disease Control and Prevention. ICD-10 Coordination and Maintenance Committee Meeting. September 10-11, 2019. Available at: https:\/\/www.cdc.gov\/nchs\/data\/icd\/Topic-packet-Sept-2019-Part2.pdf. Accessed February 24, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0023","unstructured":"Centers for Disease Control and Prevention. ICD-10 Coordination and Maintenance Committee Meeting. September 8-9, 2020. Available at: https:\/\/www.cdc.gov\/nchs\/data\/icd\/Topic-packet-September-8-9.2020.pdf. Accessed February 24, 2022."},{"key":"10.1016\/j.jtct.2022.11.004_bib0024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2022.11.004_bib0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.11.004_bib0026","unstructured":"International Classification of Diseases, 10th Revision (ICD-10) and other coding revisions to National Coverage Determinations (NCDs)\u2014April 2022 (CR 1 of 2). Available at: https:\/\/www.cms.gov\/files\/document\/mm12480-international-classification-diseases-10th-revision-icd-10-and-other-coding-revisions.pdf. Accessed August 4, 2022."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:08:56Z","timestamp":1763003336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666636722017481"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.11.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}